Subcutaneous Immunoglobulin Maintains HRQoL Among Patients With CIDP

Treatment with facilitated subcutaneous immunoglobulin (fSCIG) was found to maintain health-related quality of life (HRQOL) that patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) previously had while receiving intravenous immunoglobulin (IVIg). These are the findings of a study presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, held from November 1 to 4 in Phoenix, Arizona.

Using data from the phase 3 ADVANCE-CIDP 1 study (ClinicalTrials.gov Identifier: NCT02549170), researchers studied the effect of fSCIG on patient-reported outcomes (PROs), including treatment satisfaction, preference, and convenience, in CIDP.

Eligible study participants were patients with CIDP receiving stable doses of IVIg for 12 weeks or more. Participants were randomly assigned to receive fSCIG or placebo for 6 months or until relapse/discontinuation, whichever occurred first.

The PROs were assessed using the Rasch-built Overall Disability Scale (R-ODS), European QOL 5 Dimensions 3 Level (EQ-5D-3L) version, 36-Item Short Form (SF-36) health survey, and the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9).

Of 132 patients with CDIP, 62 received fSCIG and 70 received placebo.

Patients who received fSCIG vs placebo had higher least-squares mean changes in R-ODS scores (-0.9 vs -6.1, respectively; P =.03) from baseline to end of the study treatment. Based on EQ-5D-3L and SF-36 scores, treatment with fSCIG resulted in stable or improved HRQOL vs placebo that resulted in stable or reduced HRQOL. Median TSQM-9 scores for treatment satisfaction also remained stable with fSCIG vs decreased from baseline with placebo.

The researchers noted that 67% of patients who received fSCIG preferred it to previous treatment with IVIg, with 83% wanting to continue fSCIG.

Overall, the researchers concluded, “fSCIG maintained the HRQOL that patients with CIDP previously experienced with IVIg and demonstrated favorable treatment satisfaction, preference, and convenience.”

Disclosure: This research was supported by Takeda Pharmaceuticals International AG.